PRAX-222 - Fixed Doses
Small molecule
PRAX-222 - Fixed Doses is one of 5 small molecule programs targeting Developmental and Epileptic Encephalopathy. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Developmental and Epileptic Encephalopathy
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
LP352
LLongboard Pharmaceuticals
Phase 3
XEN496
XXenon Pharmaceuticals Inc.
Phase 3
NBI-921352
Neurocrine BiosciencesPhase 2
PRAX-222 - Fixed Doses
PPraxis Precision Medicines
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PRAX-222 - Fixed Doses. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- PPraxis Precision Medicines